The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice

A. Montero-Luis*, C. Aristei, I. Meattini, M. Arenas, L. Boersma, C. Bourgier, C. Coles, B. Cutuli, L. Falcinelli, O. Kaidar-Person, M. C. Leonardi, B. Offersen, F. Marazzi, S. Rivera, L. Tagliaferri, V. Tombolini, C. Vidali, V. Valentini, P. Poortmans

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Web of Science)

Abstract

Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second "Assisi Think Tank Meeting" (ATTM) on Breast Cancer.

Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT.

Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey.

Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5-20 years work-experience and irradiated <5 DCIS patients/year. PMRT was more given if: surgical margins <1 mm, high-grade, multicentricity, young age, tumour size > 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation).

Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume138
DOIs
Publication statusPublished - Jun 2019

Keywords

  • Breast cancer
  • Ductal carcinoma in situ
  • Post-mastectomy radiotherapy
  • Hypofractionation
  • Survey
  • BREAST-CONSERVING SURGERY
  • RADIOTHERAPY NSABP B-35
  • LONG-TERM OUTCOMES
  • LOCAL RECURRENCE
  • DOUBLE-BLIND
  • POSTMENOPAUSAL WOMEN
  • UK STANDARDIZATION
  • CANCER
  • MASTECTOMY
  • TAMOXIFEN

Cite this